Clinical Research
Along with normal clinical service, wide range of clinical trials also provided in our center
We are actively recruiting patient to participate in the following clinical trials
Please send referral letter to medicaloncology@hku.hk if interested
Recruiting clinical Trials
Liver Cancer
Protocol Number
Protocol Title
Experimental agent
Principle Investigator
RELATIVITY-073 (CA224-073)
A Phase 2, Randomized, Open-label Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Hepatocellular Carcinoma who are Naive to IO Therapy but Progressed on Tyrosine Kinase Inhibitors
Nivolumab VS Nivolumab + Relatlimab
Dr. Thomas Yau
Bile Duct Cancer
Protocol Number
Protocol Title
Experimental agent
Principle Investigator
Pancreatic Cancer
Protocol Number
Protocol Title
Experimental agent
Principle Investigator
PANOVOA-3
Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma
TTFields, 150kHz
with
Gemcitabine and nab-paclitaxel
Dr. Thomas Yau
Breast Cancer
Protocol Number
Protocol Title
Experimental agent
Principle Investigator
CA209-7FL
A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
Nivolumab
VS
Placebo
(Co-admin: standard Chemotherpay, endocrine therapy)
Dr. Joanne Chiu
BO41843
A Phase III Randomized, Double-Blind, Placebo-controlled, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Combined with Palbociclib Compared with Letrozole Combined with Palbociclib in Patients with Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Brease Cancer
GDC-9545
VS
Letrozole
(Co-admin: Palbociclib)
Dr. Roland Leung
Lung Cancer
Protocol Number
Protocol Title
Experimental agent
Principle Investigator
KeyImPaCT / KEYNOTE-495 (MK-3475-495)
A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab - (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)
pembrolizumab w/
MK-1308 (CTLA-4) or
MK-4280 (LAG3) or
lenvatinib (VEGF)
Dr. Joanne Chiu
MK-7684A-003
A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 with Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer
MK-7684A (vibostolimab + pembrolizumab)
Dr. Joanne Chiu
IMpassion030 (WO39391)
A Phase III, Multicenter, Randomised, Open-labelled STUDY Comparing Atezolizumab (Anti-PD-L1 Antibody) in combination with adjuvant Anthracycline /Taxane-based chemotherapy versus Chemotherapy Alone in patients with operable triple-negative Breast Cancer
Paclitaxel, AC/EC
+/-
Atezoliumab
Dr. Joanne Chiu
Other Solid Tumor
Protocol Number
Protocol Title
Experimental agent
Principle Investigator
CPDR001X2X01B
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments
PDR001
Dr. Joanne Chiu
IMbrella B
(BO40729)
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
Atezolizumab
Dr. Roland Leung
STARTRK-2
An Open-Label, Multicenter, Global Phase2 Basket Study of Entrectinib for the treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Entrectinib
Dr. Thomas Yau
TIDENT-1
(TPX-0005-01)
Phase 2 Study
NTRK1/2/3-/ROS-1/ALK-rearranged solid tumors
Repotrectinib
Dr. Thomas Yau
FLX475-02
Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer
FLX45
+/-
Pembrolizumab
Dr. Joanne Chiu
WP41377
A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases
RO7119929
(TLR7 Agonist)
Dr. Thomas Yau
CS1002-101
A phase IA/IB, open-label, dose-escalation, and dose-expansion study of the anti-CTLA-4 monoclonal antibody CS1002 as monotherapy and in combination with anti-PD-1 monoclonal antibody CS1003 in subjects with advanced solid tumors
CS1002 (CTLA4)
+/-
CS1003 (PD1)
Dr. Thomas Yau
CS1001/Regorafenib-101
A phase Ib/II, multicenter open-label study of CS1001 in combination with regorafenib in patients with advanced or refractory solid tumors
CS1001 (PD-L1), Regorafenib
​
Dr. Thomas Yau
YQ23-19002
A phase Ib, open-label, dose-escalation study of YQ23 as a single agent and in combination with pembrolizumab administered to patients with advanced solid tumors
YQ23
+/-
pembrolizumab
Dr. Thomas Yau
V941-001
Phase 1 Study
KRAS + NSCLC / CRC / PDAC
mRNA-5671 / V941
+/-
pembrolizumab
Dr. Joanne Chiu
4003.1
A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors
HBM4003
Dr. Thomas Yau
BA3021-001
A phase 1/2 dose escalation and dose expansion study of BA3021 alone and in combination with nivolumab in patients with advanced solid tumors
BA3021
+/-
nivolumab
Dr. Thomas Yau
IMbrave050 (WO41535)
A Phase 3, multicenter, randomised, open-label study of Atezolizumab (Anti-PD-L1 Antibody) Plus Bevacizumab versus Active Surveillance As Adjuvant Therapy in Patients with Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
Atezolizumab+ Bevacizumab
VS
Active Surveillance
Dr. Thomas Yau
KEYNOTE-937 (MK-3475-937)
A Phase 3 double-blinded, two-arm Study to evaluate the Safety and Efficacy of Pembrolizumab versus Placebo as Adjuvant Therapy in participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation
Pembrolizumab
VS
Placebo
Dr. Thomas Yau
EMERALD-2 (D910DC00001)
A Phase 3, randomised, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination with Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
Durvalumab
+/-
Bevacizumab
Dr. Thomas Yau
CA209-9DW
A Randomized, Multi-Center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma
Nivolumab, Ipilimumab
VS
Sorafenib or Lenvatinib
Dr. Thomas Yau
EMERALD-1
(D933GC00001)
A Phase 3 Randomized, Double Blind, Placebo-Controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patient with Locoregional Hepatocellular Carcinoma
Durvalumab with TACE
VS
Durvalumab, Bevacizumab with TACE
Dr. Thomas Yau
FOENIX-CCA3 (TAS-120-301)
A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements FOENIX-CCA3​
Pembrolizumab
VS
Placebo
Dr. Thomas Yau
GO42661
A Phase II, Randomized, Double-Blind Placebo-Controlled Study Of Atezolizumab With Or Without Bevacizumab In Combination With Cisplatin Plus Gemcitabine In Patients With Untreated, Advanced Biliary Tract Cancer
Atezolizumab+ Bevacizumab VS Atezolizumab + Placebo
Dr. Thomas Yau
OBI-822-011
The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients with High-Risk, Early-Stage Globo H-Positive Triple Negative Breast Cancer
OBI-822, OBI-821
VS
Placebo
Dr. Joanne Chiu
WO41554
A Phase III, Randomized, Double-Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of GDC-0077 Plus Palbociclib And Fulvestrant Versus Placebo Plus Palbociclub and Fulvestrant in Patients with PIK3CA-Mutant, Hormone receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
GDC-0077
VS
Placebo
(Co-admin: Palbociclib, Fulvestrant)
Dr. Roland Leung
20190147
A Phase 1, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects of Chinese Descent With Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation
AMG 510
Dr. Joanne Chiu